Skip to main content
Clinical Trials/NCT06743165
NCT06743165
Active, not recruiting
Not Applicable

New Generation Rehabilitation Approach in Children With Dysfunctional Voiding: Pelvic Floor Muscle Training and Dynamic Neuromuscular Stabilization Training With Transabdominal Ultrasound, a Randomized Controlled Trial

Izmir University of Economics1 site in 1 country38 target enrollmentFebruary 1, 2025

Overview

Phase
Not Applicable
Intervention
Pelvic floor muscle training with ultrasound biofeedback
Conditions
Dysfunctional Voiding
Sponsor
Izmir University of Economics
Enrollment
38
Locations
1
Primary Endpoint
Change in the amount of post-void residue
Status
Active, not recruiting
Last Updated
2 months ago

Overview

Brief Summary

The investigators hypothesize that Dynamic Neuromuscular Stabilization training, a next-generation exercise approach, and transabdominal ultrasound-guided pelvic floor muscle training (PFMT) will be more effective than PFMT guided solely by transabdominal ultrasound in reducing post-void residual volume, improving voiding disorder symptoms, and enhancing pelvic floor muscle relaxation in children with dysfunctional voiding.

Registry
clinicaltrials.gov
Start Date
February 1, 2025
End Date
June 1, 2026
Last Updated
2 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Izmir University of Economics
Responsible Party
Principal Investigator
Principal Investigator

Seda Yakit Yesilyurt

Assist. Prof.

Izmir University of Economics

Eligibility Criteria

Inclusion Criteria

  • Children aged 6-14 years,
  • Diagnosed with dysfunctional urination according to uroflowmetry measurement results and clinical examination findings,
  • Children who consent to participate in the study with the consent of their mother, father or legal guardian (legal representative) will be included in the study.

Exclusion Criteria

  • Children under 6 years of age,
  • Those with anatomical changes in the urinary system,
  • Those with spina bifida,
  • Those with a history of active urinary tract infection,
  • Those with a neurological disease,
  • Those with accompanying respiratory system disease,
  • Those with cognitive impairment,
  • Those with mental retardation,
  • Children whose bladder image is unclear in the pelvic floor evaluation with US,
  • Children who have previously undergone orthopedic surgery will not be included in the study.

Arms & Interventions

DNS Group

This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.

Intervention: Pelvic floor muscle training with ultrasound biofeedback

DNS Group

This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.

Intervention: Dynamic neuromuscular stabilization exercise

Standard exercise group

This group includes 18 children with Dysfunctional voiding, aged between 6 and 14 years.

Intervention: Pelvic floor muscle training with ultrasound biofeedback

Outcomes

Primary Outcomes

Change in the amount of post-void residue

Time Frame: From enrollment to the end of treatment at 8 weeks

After EMG-Uroflowmetry test: Post-void residual measurement will be made by transabdominal ultrasound 5 minutes after voiding. In repeated measurements, the amount of urine remaining in the bladder of 20 ml or more will be considered pathological.

Change in EMG-Uroflowmetry measurements-peak flow rate

Time Frame: From enrollment to the end of treatment at 8 weeks

EMG-Uroflowmetry test procedure: Before the test, the device will be calibrated and the scale of the interpretation sheet will be set to 1:1 for flow rate (ml/sec) and time (sec). The test will be performed in a quiet and private room and the patient will be asked to drink as much fluid as the expected bladder capacity ((age in years+1)x30) 1 hour before the test. During the test, the EMG activity of the pelvic floor muscles will also be evaluated. Voided volume (ml), peak flow rate (Q max, ml/sec) and uroflow curve interpretation will also be used. Those with decreased flow rate and stacco/interminant flow pattern will be considered pathological.

Change in EMG-Uroflowmetry measurements-Pelvic Floor EMG activity

Time Frame: From enrollment to the end of treatment at 8 weeks

EMG-Uroflowmetry test procedure: Before the test, the device will be calibrated and the scale of the interpretation sheet will be set to 1:1 for flow rate (ml/sec) and time (sec). The test will be performed in a quiet and private room and the patient will be asked to drink as much fluid as the expected bladder capacity ((age in years+1)x30) 1 hour before the test. During the test, the EMG activity of the pelvic floor muscles will also be evaluated. Recorded as (µV).

Secondary Outcomes

  • Change in EMG-Uroflowmetry measurements-uroflow curve(From enrollment to the end of treatment at 8 week)
  • Change in EMG-Uroflowmetry measurements - Voided volume(From enrollment to the end of treatment at 8 weeks)
  • Pelvic floor muscle assessment with ultrasound - maximum displacement (cm)(6 months after treatment)
  • Pelvic floor muscle assessment with ultrasound - coordination amplitude (cm)(6 months after treatment)
  • Pelvic floor muscle assessment with ultrasound - endurance amplitude (%)(6 months after treatment)
  • Gross Motor Development Stages(at baseline)
  • Change in symptom severity(6 months after treatment)
  • Pelvic floor muscle assessment with ultrasound - maximum displacement (cm)(From enrollment to the end of treatment at 8 weeks)
  • Pelvic floor muscle assessment with ultrasound - coordination amplitude (cm)(From enrollment to the end of treatment at 8 weeks)
  • Pelvic floor muscle assessment with ultrasound - endurance amplitude (%)(From enrollment to the end of treatment at 8 weeks)
  • Change in symptom severity(From enrollment to the end of treatment at 8 weeks)

Study Sites (1)

Loading locations...

Similar Trials